Provider review
Mevo Health review
Explains the difference between the two molecules carefully, then prices neither.
One floor cannot be true of both at the same cost, because a dual agonist costs more to compound.
Reviewed by Lena OrtizMetabolic Health Editor
Price updated August 2026
How we’re funded. Some links here are affiliate links: start care through one and we may earn a commission, at no extra cost to you. Affiliate partners are listed first on our rankings — what we write about a provider is the same either way, and unflattering findings about one that pays us stay in. Full disclosure.
Price as published
Mevo Health
From $199/mo, neither molecule priced separately
- Vs median
- $30/mo above the $169 median
- Market
- $59–$1300/mo across 242 of 373
- Structure
- Standard plan, self-directed low dose
- Dispensed
- Pharmacy not publicly identified
Advertising disclosure · we may earn a commission if you start care through some of these links, at no extra cost to you.
In one paragraph
The verdict
The clinical writing here is better than the pricing. Both molecules get their own description, the mechanism difference between a single-receptor agonist and a dual one is explained rather than asserted, and the account of how GLP-1s affect gastric emptying and satiety is accurate and free of the usual overstatement. You arrive understanding the choice in front of you. Then the pricing collapses that choice into one number. A single floor spanning both drugs cannot be true of both at the same price, because the dual agonist reliably costs a seller more, so either the figure belongs to the cheaper molecule with the other dearer by an unstated amount, or it describes a starting configuration the page does not set out. Either way the arithmetic you were just equipped to do cannot be done. The figure is also a floor with no ceiling, and no milligram sits behind it, which leaves the structure underneath unknowable — a starting price is equally consistent with a flat plan, a per-dose ladder, or a ladder that steepens sharply. The careful phrasing about a plan that may include a GLP-1 is accurate about how prescribing works and is worth noticing: what is priced is a program, not a guarantee of a particular drug.
Microdosing is off-label and unproven — decide with a clinician. Prices are as published by the provider when we last checked; confirm current terms before you buy.
Who it suits, and who it does not
A good fit if
- You want the difference between the two molecules explained before you choose
- You want a mid-range entry figure readable without an intake
- You want treatment decided by a physician after an evaluation rather than by a form
Look elsewhere if
- You are choosing between the two drugs on cost. One floor covers both
- You need a ceiling. Only the starting point is published
- You want the figure tied to a milligram. No dose sits behind it
What it actually costs
Price as published
"Plans starting as low as $199/month", covering compounded tirzepatide injections described as GLP-1 and GIP dual hormone therapy and compounded semaglutide injections described as a GLP-1 receptor agonist · both molecules are named and neither is priced separately, so one floor covers whichever a patient receives and the cheaper of the two cannot be identified — a single figure cannot be true of both at the same cost, because a dual agonist costs more to compound · the figure is a starting point with no ceiling published and no dose behind it · treatment is described as determined by a physician following a clinical evaluation, and the wording is that a plan "may include GLP-1–based medications" rather than that one will be prescribed
- Vs median
- $30/mo above the $169 median across the 242 of 373 programs we track that publish a plain monthly rate
- Market
- $59–$1300/mo is the full published spread in our ranking
- Structure
- Standard plan, self-directed low dose
No low-dose product of its own. Starting low means asking for a smaller amount inside a standard plan, at the standard plan's price.
152 of the 373 programs we track price a small dose this way. The clinical writing is better than the pricing: both molecules get their own description and the mechanism difference between a single-receptor agonist and a dual one is explained rather than asserted. Then one floor covers both, which cannot be true of both at the same cost because a dual agonist costs more to compound — so the comparison the page just equipped a reader to make cannot be made. The figure is a floor with no ceiling and no dose behind it, which leaves the structure underneath equally consistent with a flat plan, a per-dose ladder, or one that steepens. No low-dose product is offered.
Microdosing is off-label and unproven — decide with a clinician. Prices are as published by the provider when we last checked; confirm current terms before you buy.
What is included
- Consult
- Included in the price
- Dietitian
- Not included
- Labs
- Not required
- Pricing
- Varies by dose, plan or tier
- Price last updated
- August 2026
What it does well
- Both molecules are described accurately, including the mechanism difference between them.
- The entry figure is mid-range and readable before any intake.
- Treatment is described as physician-determined after a clinical evaluation.
Pharmacy, labs and oversight
Mevo Health does not publicly identify the pharmacy that fills its prescriptions. No bloodwork is required before you start. A clinician review is included in the price.
Transparency check
1 of 4 published openly
What Mevo Health publishes about itself, read from its own pages when we verified them — not estimated, and not a score.
- Pharmacy named and regulatedNo pharmacy is identified anywhere we could find on its own pages.
- Not published
- A price you can read before intakeThe figure appears only after an intake quiz, so it cannot be compared before signing up.
- Not published
- What a higher dose costsPriced by dose, plan or tier, and the higher rungs are not published — the advertised figure does not tell you what a larger dose costs.
- Not published
- No FDA warning letter on fileChecked against the FDA's own warning-letter database; nothing on file for this company.
- None on file
How the program works
The clinical writing here is better than the pricing. Both molecules get their own description, the mechanism difference between a single-receptor agonist and a dual one is explained rather than asserted, and the account of how GLP-1s affect gastric emptying and satiety is accurate and free of the usual overstatement. A reader arrives understanding the choice in front of them. Then the pricing collapses that choice into one number. A single floor spanning both drugs cannot be true of both at the same price, because the dual agonist reliably costs a seller more, so either the figure belongs to the cheaper molecule with the other dearer by an unstated amount, or it describes a starting configuration the page does not set out. Either way the arithmetic a reader was just equipped to do cannot be done. The figure is also a floor with no ceiling, and no milligram sits behind it, which leaves the structure underneath unknowable — a starting price is equally consistent with a flat plan, a per-dose ladder, or a ladder that steepens sharply. The careful phrasing about a plan that may include a GLP-1 is accurate about how prescribing works and is worth noticing: what is priced is a program, not a guarantee of a particular drug.
The honest cons
One floor covers both molecules, so the cheaper of the two cannot be identified.
- No ceiling is published and no dose sits behind the figure.
- The wording promises a plan that may include a GLP-1, not that one will be prescribed.
Microdosing is off-label and unproven — decide with a clinician. Prices are as published by the provider when we last checked; confirm current terms before you buy.
How it compares
Mevo Health is one of 373 low-dose GLP-1 programs we track, and 242 of them publish a monthly rate you can read before signing up. The ranking lists every published price on one screen, ordered with the companies that pay us first — a mechanism we state there, on the page it applies to.
Where this sits
#252 of 373
Ordered with the companies that pay us first, and Mevo Health is not one of them. A disclosed partition, not a score.
Compare all 373 providers →Read this before you buy
Intentional GLP-1 microdosing is off-label and unproven — no randomized trial has established that a sub-label dose does anything, and any dose belongs with a clinician who knows your history. If you are going to have that conversation, have it with real numbers.
- What microdosing GLP-1 costs
- Microdosing semaglutide
- Microdosing tirzepatide
- The true annual cost of a plan
Microdosing is off-label and unproven — decide with a clinician. Prices are as published by the provider when we last checked; confirm current terms before you buy.
The closest alternative
RxSpan MD
From $194/mo
- Vs median
- $25/mo above the $169 median
- Market
- $59–$1300/mo across 242 of 373
- Structure
- Standard plan, self-directed low dose
- Dispensed
- Pharmacy not publicly identified
Advertising disclosure · we may earn a commission if you start care through some of these links, at no extra cost to you.
Read the RxSpan MD review →Microdosing is off-label and unproven — decide with a clinician. Prices are as published by the provider when we last checked; confirm current terms before you buy.